What you need to know about securing investment for your spin out
Tim Witney
King’s College London
Tim Witney
Tim Witney is professor of molecular imaging at King’s College London and co-founder and chief scientific officer of Nuclide Therapeutics, a new biotech company recently spun-out from King’s.
Featured Resources
Venture capitalists are ‘completely different beasts’ to grant bodies so academic founders need to embrace a new style of pitching if they are to secure funding for their companies, as Tim Witney explains